Nature Medicine, Published online: 02 April 2026; doi:10.1038/s41591-026-04281-1 A prespecified analysis from the SELECT trial showed that semaglutide reduces major adverse cardiovascular events by 20% compared with placebo, particularly in patients at high risk of fibrosis, as indicated by the Fibrosis-4 index.
Nature Medicine published a clinical update in Research Highlights on 02 Apr 2026.
The item focuses on Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.
Review the original article for the full source wording and details.